BriaPro Therapeutics (2/3 owned by BriaCell) reports six-month net loss of $233K, cash only $1, going concern warning

BriaCell Therapeutics Corp.

2025-Q2 EPS reported -$5.44 vs consensus -$17.78 ▲ beat (+69.4%)

Net loss for six months ended Jan 31, 2025: $233,185; accumulated deficit $673,394.
Cash and cash equivalents only $1; total assets $192,161 mostly intangible patents.
Current liabilities $658,049 due to related party (BriaCell); warrant liability $172,991.
No revenue; R&D expenses $130,023, G&A $80,012 for six months.
Going concern warning: material uncertainty about ability to raise capital to continue operations.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.